CVE:LTY Liberty Biopharma - LTY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liberty Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. C$2.00 +2.00 (+∞) (As of 10/10/2018) Add Compare Share Share Today's RangeC$2.00▼C$2.0050-Day RangeC$2.00▼C$2.0052-Week RangeC$0.06▼C$2.74Volume700 shsAverage Volume23,286 shsMarket CapitalizationC$21.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsInsider TradesHeadlines About Liberty Biopharma (CVE:LTY) StockLiberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Read More Receive LTY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liberty Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LTY Stock News HeadlinesFebruary 28, 2023 | msn.comExplore Two American Landmarks When You Visit The Statue Of Liberty & Ellis Island In New YorkFebruary 26, 2023 | msn.comGuide to Visiting the Statue of LibertyMarch 30, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. February 2, 2023 | msn.comLiberty Twp. Hampton Inn sold to S.C. companyJanuary 27, 2023 | bizjournals.comSale price leaps by $20M for repurposed Durham warehouseNovember 1, 2022 | msn.comHow a Maryland ‘Moms for Liberty' group became leaders in our country's culture warOctober 24, 2022 | msn.comLiberty Oilfield Services (LBRT) Is Attractively Priced Despite Fast-paced MomentumOctober 19, 2022 | benzinga.comLiberty Energy Inc. Announces Third Quarter 2022 Financial and Operational ResultsMarch 30, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastOctober 17, 2022 | technews.tmcnet.comLiberty Announces Overnight Marketed Public Offering of UnitsSeptember 30, 2022 | technews.tmcnet.comLiberty Defense to Beta Test HEXWAVE System with Top US AirlineSeptember 24, 2022 | markets.businessinsider.comLiberty Advisor Group Named One of 2022 Best Places to Work in ChicagoSeptember 24, 2022 | investing.comLiberty Two Degrees (L2DJ)September 21, 2022 | seekingalpha.comLiberty Energy Is Working To Complete Turnaround StrategySeptember 9, 2022 | investing.comLiberty Financial Group Pty Ltd (LFG)September 8, 2022 | investing.comLiberty Shoes Ltd (LIBS)September 7, 2022 | nasdaq.comLiberty Latin America Ltd - Class C Shares Fall 1.0% Below Previous 52-Week Low - Market MoverSeptember 2, 2022 | apnews.comMyovant Sciences to Participate at Upcoming Investor ConferencesSeptember 1, 2022 | apnews.comLiberty HealthShare Launches Liberty Rise Sharing Program for Young AdultsAugust 29, 2022 | finance.yahoo.comEarnings Estimates Moving Higher for Liberty Oilfield Services (LBRT): Time to Buy?August 24, 2022 | finance.yahoo.comHow Much Upside is Left in Liberty Oilfield Services (LBRT)? Wall Street Analysts Think 33%August 24, 2022 | bizjournals.comLiberty Diversified names new president, CEOAugust 15, 2022 | markets.businessinsider.comLiberty Bankers Insurance Group Increases Lump Sum Benefit for Critical Illness ProductMarch 6, 2022 | ca.finance.yahoo.comUPDATE 1-Russia curbs access to BBC Russian service and Radio LibertyFebruary 28, 2022 | finance.yahoo.comDMG Bancshares, Inc. to Acquire Liberty BancorpJanuary 2, 2022 | finance.yahoo.comLetters to the editor for Friday, Dec. 31: Here's to a plant-based new yearNovember 17, 2021 | au.finance.yahoo.comEngland urged to call out Qatar’s record on human rights during 2022 World Cup by Amnesty InternationalSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LTY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liberty Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:LTY Previous SymbolCVE:VVA CUSIPN/A CIKN/A Webwww.libertybiopharma.com Phone+1-604-3777575FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio8.19 Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow2,000.00 Book ValueC$0.79 per share Price / Book2.53Miscellaneous Outstanding Shares10,770,000Free FloatN/AMarket CapC$21.54 million OptionableNot Optionable BetaN/A Key ExecutivesMr. Norman Tsui (Age 45)Pres, CEO & Director Mr. Shui Yan Tam (Age 44)Chief Financial Officer Dr. Michael T. McNamaraMedical Advisor & DirectorDr. Richard Huang Ph.D. (Age 42)Chief Technology Officer Dr. Richard Cook M.D.Msc., FRCSC, Chief Medical OfficerKey CompetitorsIBEX TechnologiesCVE:IBTSmall PharmaCVE:DMTDevonian Health GroupCVE:GSDSirona BiochemCVE:SBMAcasti PharmaCVE:ACSTView All Competitors LTY Stock - Frequently Asked Questions How have LTY shares performed in 2023? Liberty Biopharma's stock was trading at C$2.00 at the start of the year. Since then, LTY shares have increased by 0.0% and is now trading at C$2.00. View the best growth stocks for 2023 here. What other stocks do shareholders of Liberty Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Liberty Biopharma investors own include Cross Timbers Royalty Trust (CRT), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), Brigham Minerals (MNRL), Arbor Realty Trust (ABR), Advanced Emissions Solutions (ADES), Archer-Daniels-Midland (ADM), AGNC Investment (AGNC) and AMC Entertainment (AMC). What is Liberty Biopharma's stock symbol? Liberty Biopharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LTY." How do I buy shares of Liberty Biopharma? Shares of LTY stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Liberty Biopharma's stock price today? One share of LTY stock can currently be purchased for approximately C$2.00. How much money does Liberty Biopharma make? Liberty Biopharma (CVE:LTY) has a market capitalization of C$21.54 million. How can I contact Liberty Biopharma? Liberty Biopharma's mailing address is 2270-8788 McKim Way, RICHMOND, BC V6X 4E2, Canada. The official website for the company is www.libertybiopharma.com. The biotechnology company can be reached via phone at +1-604-3777575. This page (CVE:LTY) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.